Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct;40(4):805-808.
doi: 10.1002/hon.2985. Epub 2022 Mar 8.

"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies

Léopoldine Lapierre  1 , Charlotte Syrykh  2   3 , Laetitia Largeaud  3   4 , Bastien Cabarrou  5 , Thomas Filleron  5 , Lucie Oberic  1 , Salim Kanoun  6 , Lucie Coster  4 , Camille Laurent  2   3 , Benoît Branco  1 , Noémie Gadaud  1   3 , Christian Récher  1   3 , Delphine Brechemier  7 , Laurent Balardy  7 , François Vergez  3   4 , Loïc Ysebaert  1   3 , Martin Gauthier  8
Affiliations
Comment

"Accelerated phase" chronic lymphocytic leukemia: Still an intermediate risk disease in the era of targeted therapies

Léopoldine Lapierre et al. Hematol Oncol. 2022 Oct.
No abstract available

Keywords: BCL2 inhibitor; accelerated phase; chronic lymphocytic leukemia; targeted therapies.

PubMed Disclaimer

Comment on

  • Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
    Elias EE, Sarapura Martinez VJ, Amondarain M, Colado A, Cordini G, Bezares RF, Fernandez Grecco H, Custidiano MDR, Sánchez Ávalos JC, Garate G, Pavlovsky MA, Borge M, Giordano M, Gamberale R. Elias EE, et al. Cancer Immunol Immunother. 2022 Apr;71(4):979-987. doi: 10.1007/s00262-021-03043-x. Epub 2021 Aug 31. Cancer Immunol Immunother. 2022. PMID: 34467417 Free PMC article.

References

REFERENCES

    1. Gine E, Martinez A, Villamor N, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95(9):1526-1533. https://doi.org/10.3324/haematol.2010.022277
    1. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107-1120. https://doi.org/10.1056/NEJMoa1713976
    1. Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol. 2020;38(34):4042-4054. https://doi.org/10.1200/JCO.20.00948
    1. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236. https://doi.org/10.1056/NEJMoa1815281
    1. Laurent C, Baron M, Amara N, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network. J Clin Oncol. 2017;35(18):2008-2017. https://doi.org/10.1200/JCO.2016.71.2083

MeSH terms

LinkOut - more resources